Biodesix (BDSX) Price/OCF Ratio: History & Chart

Biodesix, Inc.(BDSX)

Medical - Diagnostics & Research · Louisville, CO

$29.06+1.34 (+4.83%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About Biodesix, Inc.

Biodesix, Inc. is a data-driven diagnostic solutions provider operating across the United States. Its primary focus includes a comprehensive suite of blood-based lung tests, marketed as the Nodify Lung Nodule Risk Assessment (which includes Nodify XL2 and Nodify CDT). These assessments enable clinicians to evaluate the risk of lung cancer in patients with suspicious nodules, aiding in the reclassification of malignancy risk and guiding appropriate treatment pathways. Beyond risk assessment, Biodesix offers additional lung cancer diagnostics such as GeneStrat ddPCR, which detects specific tumor mutations, and VeriStrat, which gauges the patient's immune system status. Both are crucial for establishing prognosis and informing treatment plans. Another offering is the GeneStrat NGS (Next-Generation Sequencing) test, a rapid, blood-based sequencing solution providing results within 72 hours. Through a partnership with Bio-Rad Laboratories, Inc., Biodesix also provides COVID-19 testing services under its Biodesix WorkSafe program, featuring the Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total Ab test, an antibody assay for detecting a B-cell immune response indicating recent or prior infection. Furthermore, the company extends its expertise to biopharmaceutical companies, offering diagnostic and clinical research services, alongside clinical trial testing. It also actively discovers, develops, and commercializes companion diagnostics. Originally incorporated as Elston Technologies, Inc. in 2005, Biodesix, Inc. maintains its headquarters in Boulder, Colorado.

Louisville, CO

334 employees

www.biodesix.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Scott Hutton

View full financials

NAME	MARKET CAP	PRICE/OCF RATIO	TTM	3Y	5Y
Biodesix, Inc. (BDSX)	$236.56M	N/A	N/A	N/A	N/A
BioAge Labs Inc. (BIOA)vs ›	$239.45M	N/A	N/A	N/A	N/A
Akebia Therapeutics, Inc. (AKBA)vs ›	$244.25M	5.88	7.79	7.79	7.79
Galectin Therapeutics Inc. (GALT)vs ›	$245.65M	N/A	N/A	N/A	N/A
Greenwich LifeSciences, Inc. (GLSI)vs ›	$248.21M	N/A	N/A	N/A	N/A
CAMP4 Therapeutics Corporation (CAMP)vs ›	$251.64M	N/A	N/A	N/A	N/A
Alector, Inc. (ALEC)vs ›	$220.94M	N/A	3.18	3.20	4.43
Compugen Ltd. (CGEN)vs ›	$218.42M	N/A	N/A	N/A	N/A
Eupraxia Pharmaceuticals Inc. (EPRX)vs ›	$259.30M	N/A	N/A	N/A	N/A
Anika Therapeutics, Inc. (ANIK)vs ›	$264.05M	44.18	27.05	50.78	58.49

NAME

MARKET CAP

PRICE/OCF RATIO

TTM

Biodesix, Inc. (BDSX)

$236.56M

N/A

BioAge Labs Inc. (BIOA)vs ›

$239.45M

N/A

Akebia Therapeutics, Inc. (AKBA)vs ›

$244.25M

5.88

7.79

Galectin Therapeutics Inc. (GALT)vs ›

$245.65M

N/A

Greenwich LifeSciences, Inc. (GLSI)vs ›

$248.21M

N/A

CAMP4 Therapeutics Corporation (CAMP)vs ›

$251.64M

N/A

Alector, Inc. (ALEC)vs ›

$220.94M

N/A

3.18

3.20

4.43

Compugen Ltd. (CGEN)vs ›

$218.42M

N/A

Eupraxia Pharmaceuticals Inc. (EPRX)vs ›

$259.30M

N/A

Anika Therapeutics, Inc. (ANIK)vs ›

$264.05M

44.18

27.05

50.78

58.49

Price/OCF Ratio Formula & Definition

P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.

Price/OCF Ratio: N/A

BDSX Price/OCF Ratio Metrics

BDSX Competitors' Price/OCF Ratio

Operating Cash Flow Valuation

Price/OCF Ratio Formula & Definition

Related Metrics